Behind the scenes – our Conference Team deliver their first virtual test event in their new platform. Please conta… https://t.co/sxXw8oS5N8
Levinia Crooks, CEO ASHM
Clinical posts from members and guests of the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) from various international medical and scientific conferences on HIV, AIDS, viral hepatitis, and sexual health.
update from iPrEx - more detail on drug levels
People will recall that iPrEx investigators questioned whether adherance to prophylaxis was the cause for transmissions in the active arm of the iPrEx study. Late Breaker #31LB reports on this. They compare plasma drug levels to those in an unrelated observed therapy trial STRAND with doing at 2, 4 and 7 days per week. The active arm had an overall preventative effect of 90% but when broken down by similarity to the STRAND data they found 76% efficacy at 2 day per week dosing levels, 96% at 4 and 99% at daily.
You will find the paper on the CROI Website, as well as the Oral Abstract session from 6 March 2012 in the 10am session.